Patents by Inventor Randall G. Rupp
Randall G. Rupp has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220030851Abstract: The invention is directed to methods of modulating ischemic injury in tissues and organs, including donor tissue and organs and intact tissue and organs. The invention is further directed to methods of increasing time to ischemic injury in such tissues and organs. The invention is further directed to storing and preserving donor tissues and organs. Such methods utilize compositions comprising Amnion-derived Cellular Cytokine Solution (herein referred to as ACCS). The ACCS compositions may be formulated for sustained-release, targeted-release, timed-release, extended-release, etc. and may be used alone or in combination with various suitable active agents.Type: ApplicationFiled: October 5, 2021Publication date: February 3, 2022Inventors: Richard A. Banas, David L. Steed, Randall G. Rupp, George L. Sing
-
Publication number: 20180288998Abstract: The invention is directed to methods of modulating ischemic injury in tissues and organs, including donor tissue and organs and intact tissue and organs. The invention is further directed to methods of increasing time to ischemic injury in such tissues and organs. The invention is further directed to storing and preserving donor tissues and organs. Such methods utilize compositions comprising Amnion-derived Cellular Cytokine Solution (herein referred to as ACCS). The ACCS compositions may be formulated for sustained-release, targeted-release, timed-release, extended-release, etc. and may be used alone or in combination with various suitable active agents.Type: ApplicationFiled: May 26, 2018Publication date: October 11, 2018Applicant: Noveome Biotherapeutics, Inc.Inventors: Richard A. Banas, David L. Steed, Randall G. Rupp, George L. Sing
-
Publication number: 20170035812Abstract: The invention is directed to a novel cell-derived composition having bone growth, regeneration, and repair promoting properties. In particular, the invention is directed to a novel cell-derived composition having bone growth, regeneration, and repair promoting properties termed Amnion-derived Cellular Cytokine Solution-B (ACCS-B). The invention is further directed to the use of this novel composition to promote bone growth and/or regeneration and/or repair.Type: ApplicationFiled: October 10, 2016Publication date: February 9, 2017Applicant: Noveome Biotherapeutics, Inc.Inventors: Malcolm A Meyn, III, Christopher A Fried, Donna M Olejniczak, Randall G Rupp
-
Publication number: 20160367602Abstract: The invention is directed to methods for treating Hidradenitis Suppurativa. Specifically, the invention is directed to treating and reducing inflammation associated Hidradenitis Suppurativa by administering to a subject suffering from this condition novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions).Type: ApplicationFiled: September 1, 2016Publication date: December 22, 2016Applicant: Noveome Biotherapeutics, Inc.Inventors: George L. Sing, Randall G. Rupp, David L. Steed
-
Patent number: 9464272Abstract: The invention is directed to a cell-derived composition having bone growth, regeneration, and repair promoting properties. In particular, the invention is directed to a cell-derived composition having bone growth, regeneration, and repair promoting properties termed Amnion-derived Cellular Cytokine Solution-B (ACCS-B). The invention is further directed to the use of this composition to promote bone growth and/or regeneration and/or repair.Type: GrantFiled: December 11, 2014Date of Patent: October 11, 2016Assignee: STEMNION, INC.Inventors: Malcolm A Meyn, III, Christopher A Fried, Donna M Olejniczak, Randall G Rupp
-
Publication number: 20160220617Abstract: The invention is directed to methods for treating cartilage disorders, diseases and injuries including, but not limited to, degenerative disc disease. The invention is also directed to methods for preventing cartilage disorders and diseases including, but not limited to, degenerative disc disease. The field of the invention is further directed to reducing inflammation associated with cartilage disorders, diseases and injuries including, but not limited to, degenerative disc disease.Type: ApplicationFiled: April 11, 2016Publication date: August 4, 2016Applicant: Noveome Biotherapeutics, Inc.Inventors: Donna M. Olejniczak, David L. Steed, Randall G. Rupp, George L. Sing
-
Patent number: 9314487Abstract: The invention is directed to methods for treating cartilage disorders, diseases and injuries including, but not limited to, degenerative disc disease. The invention is also directed to methods for preventing cartilage disorders and diseases including, but not limited to, degenerative disc disease. The field of the invention is further directed to reducing inflammation associated with cartilage disorders, diseases and injuries including, but not limited to, degenerative disc disease.Type: GrantFiled: May 13, 2014Date of Patent: April 19, 2016Assignee: STEMNION, INC.Inventors: Donna M Olejniczak, David L Steed, Randall G Rupp, George L Sing
-
Publication number: 20160081329Abstract: The invention is directed to methods of modulating ischemic injury in tissues and organs, including donor tissue and organs and intact tissue and organs. The invention is further directed to methods of increasing time to ischemic injury in such tissues and organs. The invention is further directed to storing and preserving donor tissues and organs. Such methods utilize compositions comprising Amnion-derived Cellular Cytokine Solution (herein referred to as ACCS). The ACCS compositions may be formulated for sustained-release, targeted-release, timed-release, extended-release, etc. and may be used alone or in combination with various suitable active agents.Type: ApplicationFiled: December 2, 2015Publication date: March 24, 2016Applicant: Stemnion, Inc.Inventors: Richard A. Banas, David L. Steed, Randall G. Rupp, George L. Sing
-
Publication number: 20160015785Abstract: The invention is directed to methods of modulating ischemic injury in tissues and organs, including donor tissue and organs and intact tissue and organs. The invention is further directed to methods of increasing time to ischemic injury in such tissues and organs. The invention is further directed to storing and preserving donor tissues and organs. Such methods utilize compositions comprising Amnion-derived Cellular Cytokine Solution (herein referred to as ACCS). The ACCS compositions may be formulated for sustained-release, targeted-release, timed-release, extended-release, etc. and may be used alone or in combination with various suitable active agents.Type: ApplicationFiled: September 16, 2015Publication date: January 21, 2016Applicant: Stemnion, Inc.Inventors: Richard A. Banas, David L. Steed, Randall G. Rupp, George L. Sing
-
Publication number: 20160000874Abstract: The invention is directed to methods of modulating ischemic injury in tissues and organs, including donor tissue and organs and intact tissue and organs. The invention is further directed to methods of increasing time to ischemic injury in such tissues and organs. The invention is further directed to storing and preserving donor tissues and organs. Such methods utilize compositions comprising Amnion-derived Cellular Cytokine Solution (herein referred to as ACCS). The ACCS compositions may be formulated for sustained-release, targeted-release, timed-release, extended-release, etc. and may be used alone or in combination with various suitable active agents.Type: ApplicationFiled: September 16, 2015Publication date: January 7, 2016Applicant: STEMNION, INC.Inventors: Richard A. Banas, David L. Steed, Randall G. Rupp, George L. Sing
-
Publication number: 20150196603Abstract: The invention is directed to novel cell compositions termed AMP-N cells. In particular, the invention is directed to novel AMP-N cell compositions and novel compositions derived from the AMP-N cells including, but not limited to, novel cell-derived conditioned medium, termed ACCS-N. The invention is further directed to novel methods for making the novel AMP-N cell and ACCS-N compositions as well as uses thereof.Type: ApplicationFiled: August 2, 2013Publication date: July 16, 2015Applicant: STEMNION, INC.Inventors: Victoria Grammer, Malcolm A Meyn, III, Randall G. Rupp
-
Publication number: 20150166951Abstract: The invention is directed to a novel cell-derived composition having bone growth, regeneration, and repair promoting properties. In particular, the invention is directed to a novel cell-derived composition having bone growth, regeneration, and repair promoting properties termed Amnion-derived Cellular Cytokine Solution-B (ACCS-B). The invention is further directed to the use of this novel composition to promote bone growth and/or regeneration and/or repair.Type: ApplicationFiled: December 11, 2014Publication date: June 18, 2015Applicant: STEMNION, INC.Inventors: Malcolm A Meyn, III, Christopher A Fried, Donna M Olejniczak, Randall G Rupp
-
Publication number: 20150079190Abstract: The invention is directed to immortalized cell compositions and compositions derived therefrom. The invention is further directed to methods of making and using such immortalized cell compositions and compositions derived therefrom. Such immortalized cell compositions include but are not limited to Immortalized Amnion-derived Multipotent Progenitor cells (herein referred to as I-AMP cells) and conditioned media derived therefrom (herein referred to as I-Amnion-derived Cellular Cytokine Solution or I-ACCS).Type: ApplicationFiled: November 20, 2014Publication date: March 19, 2015Applicant: STEMNION, INC.Inventors: Randall G. Rupp, Linda O. Palladino
-
Publication number: 20150051147Abstract: The invention is directed to methods for treating Hidradenitis Suppurativa. Specifically, the invention is directed to treating and reducing inflammation associated Hidradenitis Suppurativa by administering to a subject suffering from this condition novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions).Type: ApplicationFiled: August 12, 2014Publication date: February 19, 2015Applicant: STEMNION, INC.Inventors: George L. Sing, Randall G. Rupp, David L Steed
-
Publication number: 20140341860Abstract: The invention is directed to methods for treating cartilage disorders, diseases and injuries including, but not limited to, degenerative disc disease. The invention is also directed to methods for preventing cartilage disorders and diseases including, but not limited to, degenerative disc disease. The field of the invention is further directed to reducing inflammation associated with cartilage disorders, diseases and injuries including, but not limited to, degenerative disc disease.Type: ApplicationFiled: May 13, 2014Publication date: November 20, 2014Applicant: STEMNION, INC.Inventors: Donna M. Olejniczak, David L. Steed, Randall G. Rupp, George L. Sing
-
Publication number: 20140255904Abstract: The invention is directed to methods of modulating ischemic injury in tissues and organs, including donor tissue and organs and intact tissue and organs. The invention is further directed to methods of increasing time to ischemic injury in such tissues and organs. The invention is further directed to storing and preserving donor tissues and organs. Such methods utilize compositions comprising Amnion-derived Cellular Cytokine Solution (herein referred to as ACCS). The ACCS compositions may be formulated for sustained-release, targeted-release, timed-release, extended-release, etc. and may be used alone or in combination with various suitable active agents.Type: ApplicationFiled: March 3, 2014Publication date: September 11, 2014Applicant: Stemnion, Inc.Inventors: Richard A. Banas, David L. Steed, Randall G. Rupp, George L. Sing
-
Patent number: 8647663Abstract: The invention is directed to a novel wound healing device. In particular, the invention is directed to a novel wound healing device comprising a suture or knitted mesh that has adsorbed onto it novel cellular factor-containing compositions (referred to herein as CFC), including Amnion-derived Cellular Cytokine Solution (referred to herein as ACCS) or Physiologic Cytokine Solutions (herein referred to as PCS), as well as methods of making and uses thereof.Type: GrantFiled: November 14, 2012Date of Patent: February 11, 2014Assignee: Stemnion, Inc.Inventors: David L. Steed, Randall G. Rupp, Howard C. Wessel
-
Patent number: 8642027Abstract: The invention is directed to methods of modulating ischemic injury in tissues and organs. The invention is further directed to methods of increasing time to ischemic injury in tissues and organs. Such methods utilize compositions comprising cells capable of modulating inflammatory responses, referred to herein as Inflammatory Response Modulating Cells (IRMCs). The IRMCs any be used directly or cell membranes derived from them may be used in practicing the methods of the invention. In addition, the IRMCs and IRMC membranes may be used alone or in combination with each other and/or in combination with various suitable active agents.Type: GrantFiled: August 25, 2011Date of Patent: February 4, 2014Assignee: Stemnion, Inc.Inventors: Richard A. Banas, David L. Steed, Randall G. Rupp
-
Publication number: 20130302262Abstract: Methods for preventing, reversing, ameliorating or treating dental diseases, disorders or injuries are provided. In particular, methods for preventing, reversing, ameliorating or treating dental diseases of the gingival (gums) and bone are provided. Such methods utilize novel compositions including, but not limited to, extraembryonic cytokine-secreting cells (herein referred to as ECS cells), including, but not limited to, Amnion-derived Multipotent Progenitor cells (herein referred to as AMP cells) and conditioned media derived therefrom (herein referred to as Amnion-derived Cellular Cytokine Solution or ACCS), and Physiologic Cytokine Solution (herein referred to as PCS), each alone or in combination with each other and/or other agents.Type: ApplicationFiled: December 14, 2011Publication date: November 14, 2013Applicant: STEMNION, INC.Inventors: William J Golden, Randall G Rupp
-
Patent number: 8444417Abstract: Methods for preventing, reversing, ameliorating or treating dental diseases, disorders or injuries are provided. In particular, methods for preventing, reversing, ameliorating or treating dental diseases of the gingival (gums) and bone are provided. Such methods utilize novel compositions including, but not limited to, extraembryonic cytokine-secreting cells (herein referred to as ECS cells), including, but not limited to, Amnion-derived Multipotent Progenitor cells (herein referred to as AMP cells) and conditioned media derived therefrom (herein referred to as Amnion-derived Cellular Cytokine Solution or ACCS), and Physiologic Cytokine Solution (herein referred to as PCS), each alone or in combination with each other and/or other agents.Type: GrantFiled: December 14, 2011Date of Patent: May 21, 2013Assignee: Stemnion, Inc.Inventors: William J. Golden, Randall G. Rupp